In a recent publication in Nature communications proteomics profiling was used in an attempt to identify novel biomarkers that are associated with acute Venous thromboembolism (VTE) and linked to disease pathogenesis and risk. A case-control study derived from the VEBIOUS cohort identified the gene CFHR5 as a potentially promising VTE-associated plasma biomarker.

Venous thromboembolism (VTE) is a common, multi-causal disease that encompasses both pulmonary embolism (PE) and deep vein thrombosis (DVT). This disease has potentially serious short- and long-term complications and the only currently used plasma biomarker, the clot breakdown product D-dimer, can rule out VTE in low probability cases but not be used for confirmation of VTE diagnosis.

In this study multiplexed suspension bead arrays with HPA antibodies targeting more than 400 proteins were used on cases and controls from the VEBIOS cohort, which is a collaboration between Karolinska University Hospital, Karolinska Institute and Royal Institute of Technology (KTH), to find potential VTE biomarkers. The results identify CFHR5, a regulator of the alternative complement activation pathway, as a promising diagnostic and/or risk predictive biomarker.

Link to article